|
WO2021126973A1
(en)
*
|
2019-12-17 |
2021-06-24 |
Orionis Biosciences, Inc. |
Compounds modulating protein recruitment and/or degradation
|
|
JP2023545274A
(ja)
*
|
2020-10-07 |
2023-10-27 |
クルゲン（シャンハイ），インク． |
癌を処置する化合物および方法
|
|
WO2022152822A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Treatment of myc-driven cancers with gspt1 degraders
|
|
EP4277901A1
(en)
*
|
2021-01-13 |
2023-11-22 |
Monte Rosa Therapeutics, Inc. |
Isoindolinone compounds
|
|
CN117242060A
(zh)
*
|
2021-01-13 |
2023-12-15 |
蒙特罗萨医疗公司 |
异吲哚啉酮化合物
|
|
US20240085421A1
(en)
|
2021-01-13 |
2024-03-14 |
Monte Rosa Therapeutics, Inc. |
Methods for the identification of degrons
|
|
EP4313047A1
(en)
*
|
2021-03-22 |
2024-02-07 |
Monte Rosa Therapeutics, Inc. |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
|
WO2022256623A1
(en)
|
2021-06-04 |
2022-12-08 |
Monte Rosa Therapeutics, Inc. |
E3 ligase fusion proteins for proximity detection
|
|
CN115504963A
(zh)
*
|
2021-06-22 |
2022-12-23 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白降解剂
|
|
WO2023001028A1
(zh)
*
|
2021-07-19 |
2023-01-26 |
南京明德新药研发有限公司 |
杂芳-3-哌啶二酮类化合物及其应用
|
|
WO2023069731A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and methods of use thereof
|
|
WO2023069720A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and methods of use thereof
|
|
WO2023069700A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and methods of use thereof
|
|
WO2023069708A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and uses thereof
|
|
WO2023091567A1
(en)
|
2021-11-17 |
2023-05-25 |
Monte Rosa Therapeutics, Inc. |
Degron and neosubstrate identification
|
|
EP4508044A1
(en)
|
2022-04-14 |
2025-02-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
|
WO2024015855A1
(en)
|
2022-07-13 |
2024-01-18 |
Monte Rosa Therapeutics, Inc. |
COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
|
|
CN119630648A
(zh)
*
|
2022-07-14 |
2025-03-14 |
蒙特罗莎治疗股份有限公司 |
异吲哚啉酮衍生物的制备方法及其晶形
|
|
WO2024027795A1
(zh)
*
|
2022-08-04 |
2024-02-08 |
苏州开拓药业股份有限公司 |
包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
|
|
CN115636811A
(zh)
*
|
2022-08-17 |
2023-01-24 |
成都分迪药业有限公司 |
异吲哚啉苄胺衍生物的合成方法
|
|
KR20250099113A
(ko)
|
2022-09-09 |
2025-07-01 |
이노보 테라퓨틱스 인코포레이티드 |
CK1α 및 DUAL CK1α/GSPT1 분해 화합물
|
|
WO2024201248A1
(en)
*
|
2023-03-24 |
2024-10-03 |
Pin Therapeutics, Inc. |
Compounds and methods for degrading gspt1
|
|
WO2025051180A1
(zh)
*
|
2023-09-06 |
2025-03-13 |
上海超阳药业有限公司 |
内酰胺类衍生物及其应用
|
|
WO2025085416A1
(en)
*
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
WO2025146112A1
(en)
*
|
2024-01-05 |
2025-07-10 |
Primelink Biotherapeutics (Shenzhen) Co., Ltd. |
Gspt1 degrading compounds and compositions and uses thereof
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|